Restricted accessBrief reportFirst published online 2016-4-12
Maintenance of Cognitive Performance and Mood for Individuals with Alzheimer’s Disease Following Consumption of a Nutraceutical Formulation: A One-Year,Open-Label Study
Nutritional interventions have shown varied efficacy on cognitive performance during Alzheimer’s disease (AD). Twenty-four individuals diagnosed with AD received a nutraceutical formulation (NF: folate, alpha-tocopherol, B12, S-adenosyl methioinine, N-acetyl cysteine, acetyl-L-carnitine) under open-label conditions (ClinicalTrials.gov NCT01320527). Primary outcome was cognitive performance. Secondary outcomes were behavioral and psychological symptoms of dementia (BPSD) and activities of daily living. Participants maintained their baseline cognitive performance and BPSD over 12 months. These findings are consistent with improvement in cognitive performance and BPSD in prior placebo-controlled studies with NF, and contrast with the routine decline for participants receiving placebo.
CroisileB, AuriacombeS, Etcharry-BouyxF, VercellettoM (2011) The new 2011 recommendations of the National Institute on Aging and the Alzheimer’s Association on diagnostic guidelines for Alzheimer’s disease: Preclinical stages, mild cognitive impairment, and dementia. Rev NeurolParis168, 471–482
.
SheaTB, RogersE, RemingtonR (2012) Nutrition and dementia: Are we asking the right questions?. J Alzheimers Dis28, 423–431.
5.
MorrisMC, TangneyCC (2011) A potential design flaw of randomized trials of vitamin supplements. JAMA305, 1348–1349.
6.
ChanA, PaskavitzJ, RemingtonR, SheaTB (2008) Efficacy of a vitamin/nutriceutical formulation for early-stage Alzheimer’s disease: A one-year open-label pilot study with a 16-month extension. Am J Alz Dis Other Dementias23, 571–585.
7.
RemingtonR, ChanA, SheaTB (2009) Efficacy of a vitamin/nutriceutical formulation for moderate to late-stage Alzheimer’s disease: A placebo-controlled pilot study. Am J Alz Dis Other Dement24, 27–33.
8.
RemingtonR, BechtelC, LarsenD, LortieJJ, SamarA, DoshanjhL, FishmanP, LuoY, SmyersK, HoffmannH, BarysauskasC, BartonB, SheaTB (2015) A nutritional formulation for cognitive performance and mood in Alzheimer’s disease: A phase II multi-site randomized trial with an open-label extension. J Alzheimers Dis45, 395–405.
9.
RemingtonR, LortieJ, HoffmanH, PageR, MorrellC, SheaTB (2015) A nutritional formulation for cognitive performance in mild cognitive impairment: A placebo-controlled trial with an open-label extension. J Alzheimers Dis48, 591–595.
10.
ChanA, LeporeA, KotoyaE, ZemianekJ, RemingtonR, SheaTB (2010) Efficacy of a vitamin/nutriceutical formulation on cognitive speed and recall in adults with no known or suspected dementia. J Nutri Health Aging14, 224–230.
11.
MischoulonD, FavaM (2002) Role of S-adenosyl-L methionine in the treatment of depression: A review of the evidence. Am J Clin Nutr7611158S–1161S.
MonschAU, BondiMW, SalmonDP,
ButtersN,
ThalLJ,
HansenLA,
WiederholtWC,
CahnDA,
KlauberMR (1995) Clinical validity of the Mattis Dementia Rating Scale in detecting Dementia of the Alzheimer type. A double crossvalidation and application to a community-dwelling sample. Arch Neurol52, 899–904.
14.
CummingsJL (1997) The Neuropsychiatric Inventory: Assessing psychopathology in dementia patients. Neurology48, S10–S16.
15.
GalaskoD, BennettD, SanoM, ErnestoC, ThomasR, GrundmanM, FerrisS (1997) An inventory to assess activities of daily living for clinical trials in Alzheimer’s disease. The Alzheimer’s Disease Cooperative Study. Alzheimer Dis Assoc Disord11, S33–S39.
16.
CohenJ (1992) A power primer. Psychol Bull112, 155–159.
17.
AisenPS, SchaferKA, GrundmanM, PfeifferE, SanoM, DavisKL, FarlowMR, JinS, ThomasRG, ThalLJ, Alzheimer’s Disease Cooperative, Study
(2003) Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: A randomized controlled trial. JAMA289, 2819–2826.
18.
AlvarezXA, CacabelosR, LaredoM, CouceiroV, SampedroC, VarelaM, CorzoL, Fernandez-NovoaL, VargasM, AleixandreM, LinaresC, GranizoE, MuresanuD, MoesslerH (2006) A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer’s disease. Eur J Neurol13, 43–54.
19.
BurnsA, RossorM, HeckerJ, GauthierS, PetitH, MöllerHJ, RogersSL, FriedhoffLT (1999) The effects of donepezil in Alzheimer’s disease— results from a multinational trial. Dementia Geriatr Cogn Disord10, 237–244.
20.
ChiuCC, SuKP, ChengTC, LiuHC, ChangCJ, DeweyME, StewartR, HuangSY (2008) The effects of omega-3 fatty acids monotherapy in Alzheimer’s disease and mild cognitive impairment: A preliminary randomized double-blind placebo-controlled study. Prog Neuropsychopharmacol Biol Psychiatry32, 1538–1544.
21.
Corey-BloomJ, AnandR, VeachJ (1998) A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer’s disease. Int J Geriatr Psychopharmacol1, 55–65.
22.
DoodyRS, GavrilovaSI, SanoM, ThomasRG, AisenPS, BachurinSO, SeelyL, HungD, dimebon investigators (2008) Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer’s disease: A randomised, double-blind, placebo-controlled study. Lancet372, 207–215.
23.
DyskenMW, SanoM, AsthanaS, VertreesJE, PallakiM, LlorenteM, LoveS, SchellenbergGD, McCartenJR, MalphursJ, PrietoS, ChenP, LoreckDJ, TrappG, BakshiRS, MintzerJE, HeidebrinkJL, Vidal-CardonaA, ArroyoLM, CruzAR, ZachariahS, KowallNW, ChopraMP, CraftS, ThielkeS, TurveyCL, WoodmanC, MonnellKA, GordonK, TomaskaJ, SegalY, PeduzziPN, GuarinoPD (2014) Effect of vitamin E and memantine on functional decline in Alzheimer disease: The TEAM-AD VA cooperative randomized trial. JAMA311, 33–44.
24.
ForetteF, AnandR, GharabawiG (1999) A phase II study in patients with Alzheimer’s disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine. Eur J Neurol6, 423–429.
HommaA1, TakedaM, ImaiY, UdakaF, HasegawaK, KameyamaM, NishimuraT (2000) Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer’s disease: A 24-week, multicenter, double-blind, placebo-controlled study in Japan. Dementia Geriatr Cog Disord11, 299–313.
27.
RaskindMA, PeskindER, WesselT, YuanW (2000) Galantamine in AD. A 6-month randomised, placebo-controlled trial with a 6- month extension. Neurology54, 2261–2268.
28.
RogersSL, FarlowMR, DoodyRS, MohsR, FriedhoffLT (1998) A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Neurology50, 136–145.
29.
WinbladB, CummingsJ, AndreasenN, GrossbergG, OnofrjM, SadowskyC, ZechnerS, NagelJ, LaneR (2007) A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer’s disease–rivastigmine patch versus capsule. Int J Geriatr Psychiatry22, 456–467.
30.
RoyallDR (2014) Towards an aging-specific cognitive phenotype: The Freedom House Study. Exp Aging Res40, 245–265.
31.
TanCC, YuJT, WangHF, TanMS, MengXF, WangC, JiangT, ZhuXC, TanL (2014) Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer’s disease: A systematic review and meta-analysis. J Alzheimers Dis41, 615–631.
32.
ShintoL, QuinnJ, MontineT, DodgeHH, WoodwardW, Baldauf-WagnerS, WaichunasD, BumgarnerL, BourdetteD, SilbertL, KayeJ (2014) A randomized placebo-controlled pilot trial of omega-3 fatty acids and alpha lipoic acid in Alzheimer’s disease. J Alzheimers Dis38, 111–120.
33.
ItoK, AhadiehS, CorriganB, FrenchJ, FullertonT, TensfeldtT, Alzheimer’s Disease Working Group
(2010) Disease progression meta-analysis model in Alzheimer’s disease. Alzheimers Dement6, 39–53.
34.
ItoK, CorriganB, RomeroK, AnzianoR, NevilleJ, StephensonD, LalondeR (2013) Understanding placebo responses in Alzheimer’s disease clinical trials from the literature meta-data and CAMD database. J Alzheimers Dis37, 173–183.
35.
SafourisA, TsivgoulisG, SergentanisTN, PsaltopoulouT (2015) Mediterranean diet and risk of dementia. Curr Alzheimer Res12, 736–744.
36.
ChanA, TchantchouF, GravesV, RozenR, SheaTB (2008) Dietary and genetic compromise in folate availability reduces acetylcholine and cognitive performance: Critical role of S-adenosylmethionine. J Health Nutr Aging12, 252–261.
37.
CornelliU (2010) Treatment of Alzheimer’s disease with a cholinesterase inhibitor combined with antioxidants. Neurodegener Dis7, 193–202.
